Eli Lilly unveils £110 Foundayo in UK, heightening focus on NHS hurdles
Eli Lilly and Company introduced Foundayo in pharmacies across Britain on Monday. The oral treatment for obesity debuts at about one-third the monthly private cost of Mounjaro.
Eli Lilly Shares Drop 0.9% Following Mounjaro Cardio Approval, Raising Stakes for $9.9 Billion Franchise
Eli Lilly and Company dropped 0.9% on Friday following the news that Mounjaro received a significant cardiovascular indication. The drop wiped out approximately $9.8 billion in implied equity value.
Mounjaro's cardiovascular label meets a trillion-dollar valuation
Eli Lilly · NYSE: LLY · Market data at August 28, 2026, 09:44:26 EDT
LLY price
$1,165.73
−0.88% · −$10.37
Market value
$1.10T
941.36M shares outstanding
Value erased
~$9.76B
Observed price change × shares
Analyst consensus
$1,391.61
+19.4% implied upside
Approval and clinical evidence
| New indication | CV risk reduction in high-risk adults with type 2 diabetes |
| Comparator | Trulicity |
| MACE-3 hazard ratio | 0.92 (95.3% CI: 0.83–1.01) |
| Relative event rate | 8% lower |
| All-cause mortality | 16% lower |
| Statistical result | Noninferior; not superior |
Quarterly franchise economics
| Product | Q2 2026 sales | Growth |
|---|---|---|
| Mounjaro worldwide | $9.9B | +91% |
| Mounjaro U.S. | $4.8B | +45% |
| Mounjaro ex-U.S. | $5.2B | +172% |
| Zepbound U.S. | $4.9B | +44% |
| Lilly total | $22.97B | Quarter ended June |
Revenue concentration
Mounjaro as a share of Lilly revenue
43.3%
Mounjaro plus Zepbound as a share of Lilly revenue
64.4%
The label expansion is material because tirzepatide already supplies nearly two-thirds of quarterly revenue.
Price and valuation
| Friday open | $1,172.66 |
| Early range | $1,164.32–$1,174.00 |
| 52-week range | $712.05–$1,292.65 |
| P/E ratio | 39.22× |
| Average volume | 2.65M shares |
| Analyst ratings | 18 Buy · 2 Hold · 0 Sell |
Investor transmission
Risk monitor
Lower realized prices already offset part of U.S. volume growth. Rebate pressure, supply tightness and Novo Nordisk competition can limit incremental revenue. The medicine carries warnings including thyroid C-cell tumors and pancreatitis.
Sources: Lilly, Reuters, PubMed, Lilly Pricing Information and Google Finance. Market data are timestamped above.
NYSE:LLY · UK Foundayo launch
Private launch. Public-pay prize.
A £100–£120 monthly tablet opens Europe for Lilly. NHS reimbursement—not pharmacy availability—sets the scale.
$1,255.26-0.01% premarket
Observed 24 Aug 2026, 04:36 EDT
Prior close: $1,255.40 at 16:03:51 EDT, 21 Aug
Prior close: $1,255.40 at 16:03:51 EDT, 21 Aug
Expected monthly range
Midpoint price gap
First reported quarter
Trailing P/E
Q2 product scale · revenue
Illustrative UK gross run rate
£132m100k patients
£660m500k patients
£1.32bn1m patients
Annualised at £110 monthly. Scenario only; before discounts, dropouts, taxes and channel costs.
What the launch changes
Analyst mix · 28 ratings
22 Buy4 Hold2 Sell4.4% upside
Investor read-through
Britain validates the oral platform, but private-pay sales start small against a $86bn guidance midpoint. NICE access is the real volume gate.
What can break the case
Slow reimbursement, Novo competition, discontinuations, safety concerns or lower realised prices could expose a premium valuation.
Eli Lilly’s $67 Billion Surge Brings Shares Close to Wall Street’s Consensus Target
Eli Lilly and Company saw its market capitalization rise by about $67.1 billion over the past week. Shares climbed 6.38% to $1,255.40 as of Friday’s close, with 891.36 million shares outstanding. The stock now trades just 4.43% under the consensus one-year price target from Wall Street. The gap in valuation has rapidly closed.
Eli Lilly LLY
Obesity growth meets a narrow valuation cushion
$1,255.40 +0.88%
NYSE close · Aug. 21, 2026 · 4:00 p.m. EDT
Weekly return
+6.38%
vs. Aug. 14 close
Value added
≈$67.1B
preliminary; 891.36M shares
Market value
≈$1.12T
preliminary at Friday close
Avg. target upside
+4.43%
$1,311 consensus target
Five-session tape
Growth engine · Q2 2026
Total revenue: $22.97B, up 48%; volume +60%, realized price -13%.
Analyst target range
Consensus: Buy · 29 analysts · median target $1,372
Why the stock moved
A post-earnings rerating met fresh bullish targets. Investors priced in 48% quarterly sales growth, $85B-$87B guidance and a deeper obesity pipeline. Thursday's reversal showed how quickly profit-taking appears near records.
The investor read: operating growth remains rare, but the average target now offers only 4.43% upside. Future gains need better-than-guided volume, successful factory ramp-ups or another pipeline surprise.
Support
$1,243.23Thursday low
Record marker
$1,292.65Wednesday intraday high
Next macro check
U.S. income & inflationBEA release calendar this week
Market data: StockAnalysis / S&P Global, through Aug. 21, 2026, 4:00 p.m. EDT. Analyst consensus: S&P Global via StockAnalysis. Financials and guidance: Eli Lilly Q2 release. Market value estimates use 891.36 million shares outstanding and may differ from vendor calculations.
Eli Lilly Shares Approach High as 60% Volume Surge Offsets 13% Price Fall
Eli Lilly and Company finished Tuesday at $1,225.73, standing 1.9% under its highest level. The stock rose 3.6% as investors responded to the pharmaceutical firm's ongoing earnings strength.
Volume beats price pressure
Lilly's growth has a narrower valuation runway
Eli Lilly and CompanyNYSE:LLY
Data checked Aug. 19, 2026, 14:39 EDT. Stock price uses the Aug. 18 close at 16:00 EDT. Financial data cover Q2 ended June 30.
Aug. 18 close
$1,225.73
+3.60% daily
Below record
1.9%
Record: $1,249.45
Q2 revenue
$22.97B
+48% year over year
2026 guide
$85–87B
Raised Aug. 5
The growth bridge
Obesity franchise concentration
Mounjaro$9.9B43% of sales
Zepbound$4.9B21% of sales
Foundayo$98M0.4% of sales
Mounjaro plus Zepbound supplied roughly 64% of total quarterly revenue.
Two-day earnings reaction
Aug. 4 close$1,115.68Baseline
Aug. 5 close$1,169.86+4.86%
Aug. 6 close$1,192.80+6.91% cumulative
Aug. 18 close$1,225.73+9.86%
Wall Street's target spread
Low target$850-30.7%
Average target$1,277+4.2%
Median target$1,300+6.1%
High target$1,600+30.5%
Consensus is Buy, but the average target now offers only modest upside from the Aug. 18 close.
The investor read
Lilly is proving it can trade price for reach. Volume growth has more than offset lower realized prices. The burden now shifts to durability: prescriptions must keep rising, manufacturing must arrive on time, and Foundayo must close a large oral-market gap with Novo. At $1,225.73, the stock already discounts much of the near-term earnings beat.
Sources: Lilly Q2 results, MarketWatch, Reuters, StockAnalysis. Percentages are calculated from cited data.
Health-Care ETF Pulls Back From Record High as Losses in Smaller XLV Holdings Offset Gains Among Top Components
The State Street Health Care Select Sector SPDR ETF pulled back after touching an all-time high on Thursday. The fund hit $169.71 before ending the session at $168.38, a 0.04% decrease. The closing price was 0.78% short of its intraday high.
Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope
Shares of Eli Lilly and Company rose 0.5% to $1,226.64 early on Thursday, after six lawsuits were filed over alleged illegal sales of retatrutide, the company's experimental drug for obesity. The stock was trading 1.8% below its peak of $1,249.45.
Eli Lilly (NYSE:LLY) gains $30 billion following UK approval for Foundayo; NHS access remains pending
Eli Lilly and Company’s Foundayo received approval in Britain for weight management and type 2 diabetes on Monday. Shares last traded at approximately $1,220, up 2.9%, as of 14:19 EDT, valuing the company near $1.09 trillion.
Eli Lilly Q2 growth focus: Mounjaro and Zepbound seen as drivers for up to 98% of quarterly increase
Eli Lilly and Company is set for a tight earnings test on Wednesday. Initial projections indicate that Mounjaro and Zepbound will account for about 98% of the revenue increase in the second quarter.
Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen
Novo Nordisk’s U.S. ADR dropped 6.8% on Tuesday even after the company reported earnings that surpassed expectations. The decline indicates lingering investor doubts about the strength of its recovery.
AtaiBeckley Shares at $7.17 as Lilly Agreement Sets CVR at 42 Cents
Shares of AtaiBeckley Inc. remained flat at $7.17 as of 1 p.m. on Tuesday. This price stood 42 cents higher than Eli Lilly and Co.'s $6.75 cash offer at close.
AtaiBeckley (NASDAQ:ATAI) shares trade with Merger CVR valued near 19% of face
AtaiBeckley, previously known as Atai Life Sciences, closed at $7.22 on Friday, trading 47 cents higher than the cash element of Eli Lilly’s offer. U.S. stock markets did not open on Sunday.
TrumpRx’s 800-Drug List Masks Modest Pharma Price Exposure
TrumpRx currently includes around 10% of the branded drug portfolios offered by pharmaceutical companies taking part in the program, well below the widely cited figure of more than 800 medicines.
Eli Lilly (NYSE:LLY) Shares Rise After Atai Partnership Could Unlock $1 Billion in Milestones
NEW YORK, July 16, 2026, 5:08 p.m. EDT – Shares of Eli Lilly edged higher on Thursday after the drugmaker announced a deal with Atai Life Sciences, a partnership that may generate up to $1 billion in milestone payments.
AtaiBeckley (NASDAQ: ATAI) stock jumps on Lilly deal as market discounts milestones
AtaiBeckley Inc. jumped about 31% to $7.04 on Thursday. Eli Lilly and Co. agreed to buy the company for up to $3.8 billion.
VivoSim Labs (NASDAQ:VIVS) hits $5M milestone; company says 500% revenue jump comes off $131K base
VivoSim Labs, Inc. reported Wednesday it got a $5 million milestone payment from Eli Lilly and Company, bringing in cash worth about 1.7 times VivoSim’s equity value at Tuesday’s close and recent share count. Still, shares ended up just 3.0% at $0.8599, slipping from an open of $1.49.
Eli Lilly (LLY) Hovers Near $1,200 as Focus Stays on $50 Obesity Drug Access
Eli Lilly grabbing headlines with its four-digit stock price and split plan, but there’s a messier reality for investors. The drugmaker is giving up higher net prices in order to sell a lot more units.
Lilly (NYSE:LLY) closes holiday week near record as XLV outpaces
Eli Lilly and Company heads into the holiday-shortened week trading near its all-time highs. Last week, though, the more notable move wasn’t Lilly’s climb. Most of the buying in healthcare came from stocks outside of Lilly, even while it stayed the sector’s largest name.
Centessa (NASDAQ:CNTA) marks Eli Lilly (NYSE:LLY) CVR at 28 cents per dollar in last trade
As of 10:03 a.m. in New York, U.S. regular trading was open, following Nasdaq’s 9:30 a.m. to 4 p.m. ET session, but Centessa Pharmaceuticals plc had no new trades. Nasdaq’s CNTA market page showed no data, with the last price still at $40.50 from June 24 UTC.
Eli Lilly and Company (NYSE:LLY) stock nears Cantor target after $76 billion Friday pop
At 05:01 EDT, the New York Stock Exchange cash session had not opened. NYSE lists a 9:30 a.m. to 4:00 p.m. ET core session, and its 2026 holiday list shows the next full U.S. market closure is July 3 for Independence Day observed.
Eli Lilly (NYSE:LLY) gains $76 billion in one day as Jaypirca headlines land
Eli Lilly and Company closed at $1,208.12 on Friday, up $80.43. Markets in U.S. cash equities were closed Saturday, leaving Friday as the last pricing. About 7.73 million shares traded, coming in at roughly 2.5 times the average volume listed on Google Finance.
TechStock² Updates
